Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by GrahamBon May 01, 2024 8:41pm
150 Views
Post# 36018554

VPT Financials Take 2

VPT Financials Take 2

Reading through the financials again and trying to make sense of the Dear friendo letters, quarterlies, news releases and the published financials

can someone explain the disconnect that seems to exist?

The year end financials read:

Revenue $ 49,183 $  on total operating expenses 4,972,932

Net loss for the year $ (4,871,937)

 

Yet the second quarter financials read:

  • Significant sales to two key centres in Europe, including the largest heart center in Germany, Deutsches Herzzentrum der Charit (DHZC), German Heart Center, in Berlin, Germany and to Medical Center – University of Freiburg im Breisgau, Germany through the efforts of Ventripoint’s European Distributor, Angiopro GmbH.  
  • The Company recorded deferred sales for the six months ended June 30, 2023, of $71,986. This will be recorded as revenue when the clients accept the units. 

‘So the year end sales were down 30% over 6 months as 49k was recorded yet 71k was indicated 6 months ago???
 

What happenned 

Were the touted a German sales rejected/not approved?
were ther no sales recorded over the last 6 months?
if so....

 

How secure are the Duke sales?

I don’t see the original “sales” were recorded since the math doesn’t add up to me can someone explain

Also how can you spend almost 5 million in operating expenses yet only receive 10% of that in gross sales be sustainable ?

all imo
my analysis'fwiw'
do your own dd

 

<< Previous
Bullboard Posts
Next >>